Reported Tuberculosis in the United States, 2019

Return to Main Menu

Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 20171

Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2017
Reporting Area Total Cases Therapy ≤1 Year Indicated2,3,4 Therapy >1 Year Indicated3,5
No. COT ≤1 year(%) COT(%) No. COT(%)
United States 9,082 7,399 (89.8) (95.8) 531 (94.2)
Alabama 120 107 (87.9) (95.3) 5 (100.0)
Alaska 53 47 (91.5) (93.6) 3 (100.0)
Arizona 188 146 (92.5) (97.3) 9 (100.0)
Arkansas 85 76 (78.9) (85.5) 2 (100.0)
California 2,057 1,663 (90.0) (96.6) 108 (93.5)
Colorado 84 68 (91.2) (94.1) 5 (100.0)
Connecticut 63 49 (98.0) (100.0) 4 (100.0)
Delaware 15 9 (100.0) (100.0) 3 (100.0)
District of Columbia 36 30 (76.7) (93.3) 1 (100.0)
Florida 549 454 (95.2) (97.6) 28 (96.4)
Georgia 293 240 (86.3) (95.4) 19 (100.0)
Hawaii 116 97 (96.9) (99.0) 9 (100.0)
Idaho 10 9 (88.9) (100.0) 1 (0.0)
Illinois 334 273 (91.2) (97.1) 11 (72.7)
Indiana 100 84 (96.4) (98.8) 5 (80.0)
Iowa 47 39 (97.4) (100.0) 3 (100.0)
Kansas 29 21 (100.0) (100.0) 6 (100.0)
Kentucky 65 49 (98.0) (100.0) 4 (100.0)
Louisiana 141 119 (82.4) (91.6) 4 (25.0)
Maine 14 9 (100.0) (100.0) 2 (100.0)
Maryland 207 172 (84.3) (93.6) 11 (90.9)
Massachusetts 209 168 (94.6) (99.4) 22 (90.9)
Michigan 133 99 (96.0) (96.0) 8 (87.5)
Minnesota 178 138 (95.7) (100.0) 22 (100.0)
Mississippi 52 44 (86.4) (90.9) 5 (100.0)
Missouri 87 72 (73.6) (84.7) 6 (100.0)
Montana 3 3 (100.0) (100.0) 0
Nebraska 22 15 (66.7) (80.0) 4 (75.0)
Nevada 80 66 (98.5) (98.5) 3 (100.0)
New Hampshire 19 17 (88.2) (88.2) 1 (100.0)
New Jersey 283 212 (92.9) (97.6) 19 (94.7)
New Mexico 37 25 (96.0) (100.0) 0
New York State6 193 162 (92.6) (98.8) 13 (100.0)
New York City 608 494 (92.9) (97.4) 49 (93.9)
North Carolina 213 187 (93.6) (97.3) 12 (100.0)
North Dakota 14 13 (92.3) (100.0) 0
Ohio 149 124 (82.3) (91.1) 8 (87.5)
Oklahoma 54 48 (95.8) (100.0) 5 (100.0)
Oregon 69 61 (90.2) (100.0) 3 (100.0)
Pennsylvania 192 156 (75.6) (92.3) 6 (66.7)
Rhode Island 13 9 (77.8) (88.9) 0
South Carolina 101 87 (92.0) (96.6) 4 (100.0)
South Dakota 14 11 (100.0) (100.0) 1 (100.0)
Tennessee 124 105 (95.2) (99.0) 6 (100.0)
Texas 1,119 898 (82.6) (90.6) 50 (96.0)
Utah 29 24 (95.8) (100.0) 4 (100.0)
Vermont 3 2 (50.0) (100.0) 0
Virginia 204 176 (97.2) (98.9) 17 (100.0)
Washington 207 167 (93.4) (95.2) 13 (92.3)
West Virginia 16 13 (84.6) (100.0) 1 (100.0)
Wisconsin 49 40 (90.0) (100.0) 6 (100.0)
Wyoming 2 2 (100.0) (100.0) 0
American Samoa7 2 1 (0.0) (0.0) 0
Fed. States of Micronesia7 143 129 (94.6) (94.6) 5 (100.0)
Guam7 84 74 (91.9) (94.6) 1 (100.0)
Marshall Islands7 193 181 (31.5) (32.0) 3 (0.0)
N. Mariana Islands7   41 39 (94.9) (94.9) 0
Puerto Rico7 40 30 (73.3) (96.7) 0
Republic of Palau7 20 16 (93.8) (93.8) 0
U.S. Virgin Islands7 2 2 (0.0) (0.0) 0

1Most recent year for which data are available.
2Initial isolate susceptible to rifampin (n = 5,497) or susceptibility unknown (n = 166); culture negative (n = 1,359); culture status unknown (n = 363).
3Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed.
4Therapy ≤1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy. Excludes persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment.
5Initial isolate rifampin resistant, or patient with meningeal disease or bone and joint disease, or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who did not move out of the country or die during treatment.
6Excludes New York City.
7Not included in U.S. totals.

Note: Ellipses (…) indicate that the percentage cannot be calculated, and the denominator is 0.
Zero % (0.0) denotes <0.05%.

See Technical Notes for description of completion of therapy calculation.